AtriCure Reports Strong Q2 Earnings and Raises Full-Year Guidance
AtriCure (NASDAQ:ATRC) reported strong second-quarter results for fiscal year 2026 on July 23, with revenue of $153.6 million and adjusted EPS of $0.18, both exceeding consensus estimates by a significant margin. The company turned a net loss in the prior-year period into a profit of $9 million and reported an impressive gross margin increase to 77.2%. Growth was driven across multiple franchises including pain management (up 27% globally) and appendage management (14% growth). AtriCure also raised its full-year guidance, now expecting revenue between $602 million and $610 million with adjusted EBITDA of $85–$89 million. Looking ahead, the company is advancing two key clinical trials—BoxX-NoAF and LeAAPS—which could expand AtriCure’s market in cardiac surgery. These initiatives aim to broaden label indications for its products and support long-term growth potential. Additionally, management anticipates continued gross margin improvements despite initial costs from a new manufacturing facility. Despite the positive momentum, competition remains a risk as larger firms like Edwards Lifesciences (NYSE:EW) and Medtronic (NYSE:MDT) have launched competing LAA closure systems. However, analysts suggest these launches may not significantly impact AtriCure’s market position.